Respiri (ASX:RSH) - Ambassador, Michael Clarke
Ambassador, Michael Clarke
Source: Respiri
The Market Online - At The Bell

Join our daily newsletter At The Bell to receive exclusive market insights

  • Respiri (RSH) has signed a merchant services agreement with buy now, pay later giant Zip Co’s (Z1P) subsidiary, Zip Money Payments
  • As more businesses in Australia’s pharmacy industry are providing buy now, pay later services, Respiri thought it was time to do the same
  • The e-Health company considers the latest agreement important in providing flexible payments options for people to access its wheezo device
  • This agreement follows an international sales agreement with Cipla Australia
  • Company shares are up 13.8 per cent and are trading for 16.5 cents each

Respiri (RSH) has signed a merchant services agreement with buy now, pay later giant Zip Co’s (Z1P) subsidiary, Zip Money Payments.

Respiri is an e-Health software-as-a-solution (SaaS) company supporting respiratory health management.

Its world-first technology detects wheezing, which is a typical symptom of asthma, chronic obstructive pulmonary disease (COPD) and respiratory disease to accurately measure airway limitations.

This agreement follows a recently signed exclusive international sales agreement with Cipla Australia.

Under the agreement, Cipla will order at least 2000 wheezo devices from Respiri.

“The recently announced pharmacy sales and marketing, distribution and logistics agreement with Cipla Australia is expected to significantly increase both pharmacy awareness and patient access to our proprietary wheezo device alongside our training and education initiatives with the Pharmacy Guild of Australia,” CEO Marjan Mikel said.

Respiri considers the latest agreement a way to provide people, no matter their financial situation, with its wheezo device.

“Our agreement with ZIP provides asthmatic patients seeking access to our platform additional financial flexibility when making these important healthcare decisions relating to improvements in the management of their disease,” Marjan stated.

Buy now, pay later services are on the rise in the Australian pharmacy segment; around one in 10 of the general population now utilise flexible payment options.

Company shares are up 13.8 per cent and are trading for 16.5 cents each at 1:12 pm AEST.

RSH by the numbers
More From The Market Online

ResMed spikes on robust results and global growth spurt

ResMed shares have climbed following the release of the company's strong Third Quarter FY2024 results.

PharmAust CEO’s sayanora triggers stock plunge

Clinical-stage biotechnology company, PharmAust shares plunged 24 per cent so this morning, following the resignation of…

Recce wins safety board approval to dose 4g in R327 UTI infusion trial

Recce Pharma will dose patients with 4g of its R327 intravenous solution to treat UTIs in…

Emyria locks in $2.3M to progress MDMA research – with Chair adding $0.3M

WA-based and ASX-listed Emyria is seeking to further research using MDMA to treat PTSD. The chair…